Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin in Pediatric Recurrent/Refractory Brain Tumors
NCT00047177Phase 2Completed
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Oct 2002
- Primary completion
- Aug 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in medulloblastoma, supratentorial primitive neuroectodermal tumor (sPNET) and Atypical teratoid rhabdoid tumor (ATRT), sponsored by Pediatric Brain Tumor Consortium. Primary endpoint: Objective Response Rate. Started Oct 2002; status: completed.
02
Drugs
oxaliplatin
03
Conditions
medulloblastomasupratentorial primitive neuroectodermal tumor (sPNET)Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT00047177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047177.